FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Antoine Verger; Igor Yakushev; Nathalie L Albert; Bart van Berckel; Matthias Brendel; Diego Cecchin; Pablo Aguiar Fernandez; Francesco Fraioli; Eric Guedj; Silvia Morbelli; Nelleke Tolboom; Tatjana Traub-Weidinger; Donatienne Van Weehaeghe; Henryk Barthel

doi:10.1007/s00259-023-06177-5

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Antoine Verger, Igor Yakushev^*, Nathalie L Albert, Bart van Berckel, Matthias Brendel, Diego Cecchin, Pablo Aguiar Fernandez, Francesco Fraioli, Eric Guedj, Silvia Morbelli, Nelleke Tolboom, Tatjana Traub-Weidinger, Donatienne Van Weehaeghe, Henryk Barthel

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › Academic › peer-review

1 Downloads (Pure)

Original language	English
Pages (from-to)	1553-1555
Number of pages	3
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	50
Issue number	6
DOIs	https://doi.org/10.1007/s00259-023-06177-5
Publication status	Published - May 2023

Keywords

Alzheimer Disease/diagnostic imaging
Amyloid
Amyloid beta-Peptides
Humans
Neuroimaging
Positron-Emission Tomography

Access to Document

10.1007/s00259-023-06177-5Licence: CC BY

s00259-023-06177-5Final published version, 372 KBLicence: CC BY

Cite this

Verger, A., Yakushev, I., Albert, N. L., van Berckel, B., Brendel, M., Cecchin, D., Fernandez, P. A., Fraioli, F., Guedj, E., Morbelli, S., Tolboom, N., Traub-Weidinger, T., Van Weehaeghe, D., & Barthel, H. (2023). FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective. European Journal of Nuclear Medicine and Molecular Imaging, 50(6), 1553-1555. https://doi.org/10.1007/s00259-023-06177-5

@article{1fef040ab26f4a4bb8a102848eb77961,

title = "FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective",

keywords = "Alzheimer Disease/diagnostic imaging, Amyloid, Amyloid beta-Peptides, Humans, Neuroimaging, Positron-Emission Tomography",

author = "Antoine Verger and Igor Yakushev and Albert, {Nathalie L} and {van Berckel}, Bart and Matthias Brendel and Diego Cecchin and Fernandez, {Pablo Aguiar} and Francesco Fraioli and Eric Guedj and Silvia Morbelli and Nelleke Tolboom and Tatjana Traub-Weidinger and {Van Weehaeghe}, Donatienne and Henryk Barthel",

year = "2023",

month = may,

doi = "10.1007/s00259-023-06177-5",

language = "English",

volume = "50",

pages = "1553--1555",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "Springer-Verlag",

number = "6",

}

Verger, A, Yakushev, I, Albert, NL, van Berckel, B, Brendel, M, Cecchin, D, Fernandez, PA, Fraioli, F, Guedj, E, Morbelli, S, Tolboom, N, Traub-Weidinger, T, Van Weehaeghe, D & Barthel, H 2023, 'FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 6, pp. 1553-1555. https://doi.org/10.1007/s00259-023-06177-5

TY - JOUR

T1 - FDA approval of lecanemab

T2 - the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

AU - Verger, Antoine

AU - Yakushev, Igor

AU - Albert, Nathalie L

AU - van Berckel, Bart

AU - Brendel, Matthias

AU - Cecchin, Diego

AU - Fernandez, Pablo Aguiar

AU - Fraioli, Francesco

AU - Guedj, Eric

AU - Morbelli, Silvia

AU - Tolboom, Nelleke

AU - Traub-Weidinger, Tatjana

AU - Van Weehaeghe, Donatienne

AU - Barthel, Henryk

PY - 2023/5

Y1 - 2023/5

KW - Alzheimer Disease/diagnostic imaging

KW - Amyloid

KW - Amyloid beta-Peptides

KW - Humans

KW - Neuroimaging

KW - Positron-Emission Tomography

UR - http://www.scopus.com/inward/record.url?scp=85149212696&partnerID=8YFLogxK

U2 - 10.1007/s00259-023-06177-5

DO - 10.1007/s00259-023-06177-5

M3 - Editorial

C2 - 36869178

SN - 1619-7070

VL - 50

SP - 1553

EP - 1555

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 6

ER -

FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective

Keywords

Access to Document

Other files and links

Cite this